May 29, 2020

The Niche

Knoepfler lab stem cell blog

Athersys

1 min read

I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stock ticker for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post. Quite a few stem cell-related stocks could not be added to this ticker for various reasons including ACTC, Mesoblast, CUR, and others. Yahoo has limits on which stocks can be included based on company size and which exchange they are …Read More

2 min read

The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal, reportedly worth up to $100 million if specific milestones are reached in clinical trials in the future, will boost Mesoblast’s leadership in MSC-related clinical applications, although Mesoblast, led by …Read More

3 min read

Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through the US v. Regenerative Sciences Inc. (RSI) case providing helpful and insightful perspectives on the history of the case and their prediction as to the likely outcome on appeal. …Read More

11 min read

Today’s post is an interview I did with Dr. Van Bokkelen covering 10 questions. Dr. Gil Van Bokkelen is Chairman and CEO of Athersys, Inc., a company that has focused heavily on stem cells and regenerative medicine for more than a decade. For more on Dr. Van Bokkelen’s background see additional bio section at the end of this post. 1. Why stem cells? Of all the biotech areas you could have worked on, what inspired you to work on stem cells? Was there a defining moment, …Read More